A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer (Excluding Biliary Tract Cancer) Patients With FGFR Alterations Who Have Failed Standard Therapy
Latest Information Update: 30 Sep 2022
At a glance
- Drugs Pemigatinib (Primary)
- Indications Gastrointestinal cancer
- Focus Therapeutic Use
Most Recent Events
- 30 Sep 2022 New trial record